(2E)-3-(4-Methoxyphenyl)-1-phenylprop-2-en-1-one
CAS: 22252-15-9
Ref. 3D-XAA25215
| 5g | To inquire | ||
| 10g | To inquire | ||
| 25g | To inquire |
Estimated delivery in United States, on Tuesday 7 Jan 2025
Product Information
Name:
(2E)-3-(4-Methoxyphenyl)-1-phenylprop-2-en-1-one
Synonyms:
- 2-Propen-1-one, 3-(4-methoxyphenyl)-1-phenyl-, (2E)-
- (2E)-3-(4-Methoxyphenyl)-1-phenyl-2-propenone
- (E)-3-(4-Methoxyphenyl)-1-phenyl-2-propen-1-one
- NSC170287
- (E)-4-Methoxychalcone
- Chalcone, 4-methoxy-, (E)-
- 2-Propen-1-one,3-(4-methoxyphenyl)-1-phenyl-, (E)-
- (2E)-3-(4-Methoxyphenyl)-1-phenyl-2-propen-1-one
- trans-4-Methoxychalcone
- Chalcone, 4-methoxy-, (E)- (8CI)
- See more synonyms
- (2E)-3-(4-Methoxyphenyl)-1-phenyl-2-propen-1-one
- 2-Propen-1-one, 3-(4-methoxyphenyl)-1-phenyl-, (E)-
- (E)-3-(4-Methoxyphenyl)-1-phenyl-2-propen-1-one
Description:
(2E)-3-(4-Methoxyphenyl)-1-phenylprop-2-en-1-one is a molecule that regulates inflammatory response and insulin sensitivity. It has been shown to inhibit the production of TNF-α, which is an important factor in inflammation. (2E)-3-(4-Methoxyphenyl)-1-phenylprop-2-en-1-one also inhibits the production of insulin, which may cause insulin resistance. This substance has been found to have anti cancer properties in mice, but has not been tested on humans.
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:
Chemical properties
Molecular weight:
238.28 g/mol
Formula:
C16H14O2
Purity:
Min. 95%
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: 3D-XAA25215 (2E)-3-(4-Methoxyphenyl)-1-phenylprop-2-en-1-one
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
